1. Home
  2. ALX vs ANL Comparison

ALX vs ANL Comparison

Compare ALX & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alexander's Inc.

ALX

Alexander's Inc.

HOLD

Current Price

$248.37

Market Cap

1.2B

Sector

Real Estate

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$10.58

Market Cap

998.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALX
ANL
Founded
1928
2004
Country
United States
Singapore
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
998.8M
IPO Year
1994
2022

Fundamental Metrics

Financial Performance
Metric
ALX
ANL
Price
$248.37
$10.58
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $29.50
AVG Volume (30 Days)
24.1K
★ 308.7K
Earning Date
11-02-2026
08-14-2026
Dividend Yield
★ 7.28%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 31.15
N/A
Revenue
★ $213,183,000.00
N/A
Revenue This Year
$14.78
$243.83
Revenue Next Year
N/A
N/A
P/E Ratio
$7.93
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$201.28
$0.88
52 Week High
$289.43
$17.25

Technical Indicators

Market Signals
Indicator
ALX
ANL
Relative Strength Index (RSI) 53.43 35.97
Support Level $242.66 $8.96
Resistance Level $251.32 $12.49
Average True Range (ATR) 4.70 1.37
MACD 1.49 -0.35
Stochastic Oscillator 85.65 5.05

Price Performance

Historical Comparison
ALX
ANL

About ALX Alexander's Inc.

Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing, and redeveloping its properties. It has five properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City, which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: